Med-Chemist : "Quintessential Medicinal Chemistry"
Thursday, May 16, 2019
Dual-Drug Therapy May Boost Odds Against a Tough Breast Cancer
›
In continuation of my updates on fulvestrant ( Faslodex ) and anastrozole ( Arimidex ) There's good n...
Wednesday, May 15, 2019
Mavenclad Approved for Multiple Sclerosis
›
In continuation of my update on Mavenclad ( cladribine) Mavenclad ( cladribine ) tablets have been approved by the U.S. Foo...
Tuesday, May 14, 2019
Celgene Submits Application to FDA for Ozanimod for the Treatment of Relapsing Forms of Multiple Sclerosis
›
In continuation of my update on ozanimod Celgene Corporation (NASDAQ:CELG) announced that the Company has submitted a New Drug Ap...
Monday, May 13, 2019
Eisai and Imbrium Therapeutics Announce U.S. FDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia
›
In continuation of my update on lemborexant Eisai Co., Ltd. (CEO: Haruo Naito, “Eisai”) and Imbrium Therapeutics L.P. (Imbriu...
Friday, May 10, 2019
FDA Approves Mayzent (siponimod) for Secondary Progressive Multiple Sclerosis
›
Novartis announced that the US Food and Drug Administration (FDA) has approved Mayzent (siponimod) for the treatment of adults with rel...
Wednesday, May 8, 2019
U.S. FDA Grants Priority Review for Fedratinib New Drug Application in Myelofibrosis
›
Celgene Corporation (NASDAQ:CELG) announced the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application ...
Tuesday, May 7, 2019
TB Medicine Pretomanid Enters Regulatory Review Process in the United States
›
TB Alliance’s new drug application (NDA) for the novel tuberculosis (TB) drug candidate pretomanid has been accepted for review by the U...
Monday, May 6, 2019
Intellipharmaceutics Announces Resubmission of New Drug Application to the U.S. FDA for its Oxycodone ER
›
In continuation of my update on Oxycodone ER ntellipharmaceutics International Inc. (NASDAQ: IPCI, TSX: IPCI) ("Intellip...
Friday, May 3, 2019
Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine
›
Allergan plc (NYSE: AGN) announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Applicati...
Thursday, May 2, 2019
Karyopharm Announces FDA Extension of Review Period for Selinexor New Drug Application
›
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a clinical-stage pharmaceutical company, announced that the U.S. Food and...
Wednesday, May 1, 2019
FDA Issues Complete Response Letter for Zynquista (sotagliflozin)
›
In continuation of my update on Zynquista ( sotagliflozin ) The U.S. Food and Drug Administration (FDA) issu ed a Complete Resp...
‹
›
Home
View web version